Century Therapeutics to Present CNTY-813 Research at Major Diabetes Conferences
The company has been selected to share preclinical data on CNTY-813, an experimental Type 1 diabetes treatment, at two significant 2026 conferences focused on diabetes research and care.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Century Therapeutics will present CNTY-813 preclinical data at EASD 2026 and Breakthrough T1D Clinical & Research Congress 2026
- The selection for oral presentations indicates the research has met scientific review standards for these conferences
- This is an early-stage preclinical candidate; human studies would follow if development continues
Research Moving Into the Spotlight
Century Therapeutics has been selected to present oral presentations of preclinical data on CNTY-813 at two major conferences in 2026. The presentations will be featured at the European Association for the Study of Diabetes (EASD) 2026 conference and the Breakthrough T1D Clinical & Research Congress 2026.
Selection for oral presentation at these conferences is competitive and reflects that the research meets scientific standards worthy of discussion among diabetes researchers, clinicians, and advocates.
What This Means for Development
CNTY-813 remains in the preclinical stage, meaning it has been studied in laboratory and animal models but has not yet entered human clinical trials. Preclinical research is an essential early step in drug development, helping scientists understand how a candidate works before testing its safety and effectiveness in people.
Sharing preclinical findings at major conferences allows the scientific community to review the data, ask questions, and build the evidence base that supports the next phases of research.
Evidence label
Origin: Investing News Network (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Cure & AdvancementsCell Replacement Therapy: A New Frontier in Type 1 Diabetes ResearchVideo report, corroborated with 5 indexed studies
- Cure & AdvancementsWhy Beta Cells Die in Type 1 Diabetes While Alpha Cells SurviveNews report, corroborated with 2 indexed studies
- Cure & AdvancementsEarly Trial Shows Some People with Type 1 Diabetes Can Reduce or Stop Insulin—Here's What We KnowNews report, corroborated with 3 indexed studies
- Cure & AdvancementsBeta Cell Therapy: Moving From Lab Promise to Real-World TreatmentVideo report, corroborated with 2 indexed studies
- Cure & AdvancementsUnderstanding the Eleodon Trial: What Early Results ShowVideo report — unverified, pending corroboration
- Cure & AdvancementsIslet Cell Therapies Advance: What You Need to KnowNews report, corroborated with 3 indexed studies